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Objectives We sought to define the cardiometabolic phenotype associated with rs5068, a genetic variant of the atrial natri-
uretic peptide (ANP) gene.
Background The ANP and B-type natriuretic peptide play an important role in cardiorenal homeostasis but also exert meta-
bolic actions.
Methods We genotyped 1,608 randomly selected residents from Olmsted County, Minnesota. Subjects were well-
characterized.
Results Genotype frequencies were: AA 89.9%, AG 9.7%, and GG 0.4%; all subsequent analyses were AA versus AGGG. The
G allele was associated with increased plasma levels of N-terminal pro-atrial natriuretic peptide (p  0.002), after
adjustment for age and sex. The minor allele was also associated with lower body mass index (BMI) (p  0.006),
prevalence of obesity (p  0.002), waist circumference (p  0.021), lower levels of C-reactive protein (p  0.027),
and higher values of high-density lipoprotein cholesterol (p  0.019). The AGGG group had a lower systolic blood
pressure (p  0.011) and lower prevalence of myocardial infarction (p  0.042). The minor allele was associated
with a lower prevalence of metabolic syndrome (p  0.025). The associations between the G allele and high-density
lipoprotein cholesterol, C-reactive protein values, myocardial infarction, and metabolic syndrome were not significant,
after adjusting for BMI; the associations with systolic blood pressure, BMI, obesity, and waist circumference remained
significant even after adjusting for N-terminal pro-atrial natriuretic peptide.
Conclusions In a random sample of the general U.S. population, the minor allele of rs5068 is associated with a favorable
cardiometabolic profile. These findings suggest that rs5068 or genetic loci in linkage disequilibrium might affect
susceptibility for cardiometabolic diseases and support the possible protective role of natriuretic peptides by
their favorable effects on metabolic function. Replication studies are needed to confirm our findings. (J Am
Coll Cardiol 2011;58:629–36) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.011Since the discovery of atrial natriuretic peptide (ANP) and
B-type natriuretic peptide (BNP) over 2 decades ago, the
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balance and cardiac structure has been clearly established (1–3).
Both ANP and BNP are secreted by the heart and are
endogenous ligands for the particulate guanylyl cyclase-A
receptor, mediating their biological actions via the second
messenger 3=,5= cyclic guanosine monophosphate (cGMP) and
consequent activation of cGMP-dependent protein kinase,
phosphodiesterases, and ion channels. Their actions include
vasodilation, natriuresis, suppression of the renin-angiotensin-
aldosterone system, and inhibition of both cardiomyocyte
hypertrophy and cardiac fibroblast activation (4).
The natriuretic peptide precursor A gene (NPPA) lies in
tandem with the BNP gene on chromosome 1 and encodes
for the prohormone from which ANP and N-terminal
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proANP) are derived in equimo-
lar amounts (5). Most recently,
Newton-Cheh et al. (6) reported
in a seminal study that 2 com-
mon genetic variants in the 3=
untranslated region and 2 kilo-
base downstream of NPPA—the
single nucleotide polymorphisms
(SNPs) rs5068 and rs198358, re-
spectively—are associated with
increased circulating levels of NT-
proANP, N-terminal pro–B-type
natriuretic peptide (NT-proBNP),
lower blood pressure (BP), and
reduced prevalence of hyperten-
sion. This recent study under-
scores the importance of ANP and
BNP in BP homeostasis as well as
the impact of common genetic
variations on cardiovascular func-
tion as predicted from the early
studies in mouse models in which
ANP gene disruption resulted in
increased BP (4,7).
Increasing evidence supports
the view that both ANP and
BNP might also play a funda-
mental role in metabolic regula-
tion. Indeed, low levels of ANP infusion in healthy volun-
teers increase free fatty acids mobilization and lipid
oxidation (8). In humans with heart failure, ANP infusion
results in increased circulating levels of the adipokine
adiponectin (9), which is an important regulator of glucose
and lipid metabolism and possesses anti-hypertrophic prop-
erties in cardiomyocytes (10–12). In mice, activation of the
guanylyl cyclase-A receptor has been shown to slow gastric
emptying (13). Most recently, Miyashita et al. (14) demon-
strated in a mouse model that BNP overexpression pre-
vented the development of obesity in response to a high fat
diet. Moreover, in humans, rs198389—an SNP in the
promoter region of the BNP gene that increases circulating
BNP—is associated with reduced risk for type 2 diabetes
mellitus (15,16).
The impact of rs5068 on the metabolic phenotype in the
general population is unknown. In the current study we
hypothesized that rs5068, which has previously been asso-
ciated with higher levels of ANP and BNP and lower BP, is
also associated with a protective cardiometabolic phenotype
in the general population. To test this hypothesis, we used
a subset of a large, well-characterized sample of the general
population 45 years and older from Olmsted County,
Minnesota both to reconfirm the elegant studies of
Newton-Cheh et al. (6) on BP and to extend our studies to
define the cardiometabolic phenotype of rs5068 in the
Abbreviations
and Acronyms
ANP  atrial natriuretic
peptide
BMI  body mass index
BNP  B-type natriuretic
peptide
BP  blood pressure
cGMP  3=,5= cyclic
guanosine monophosphate
CRP  C-reactive protein
DNA  deoxyribonucleic
acid
HDL  high-density
lipoprotein
LV  left ventricular
NPPA  natriuretic peptide
precursor A gene
NT-proANP  N-terminal
pro-atrial natriuretic
peptide
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
SBP  systolic blood
pressure
SNP  single nucleotide
polymorphismgeneral community (17).Methods
This study was approved by the Mayo Clinic Institutional
Review Board.
Study population. We analyzed a subset of a clinically
well-characterized population-based sample of the general
population 45 years or older living in Olmsted County,
Minnesota from 1997 to 2000. This population was first
characterized as part of the National Institutes of Health-
funded “Prevalence of Left Ventricular Dysfunction Study”
and “Cardiac Peptides in Cardiorenal Regulation” (RO1
HL55502 and HL36634). The design and selection criteria
of the aforementioned study as well as the characteristics of
the Olmsted County population have been previously de-
scribed (17,18). This population was characterized clinically
and biochemically and by echocardiography. From the
2,027 subjects in this study from whom there were collected
deoxyribonucleic acid (DNA) samples, a total of 1,608
subjects were successfully genotyped and were included in
this study.
Body mass index (BMI) was measured as kilograms/
meter squared. Obesity was defined as BMI 30 kg/m2.
Waist circumference was measured in centimeters at the
top of the umbilicus. In accordance with the National
Cholesterol Education Program Adult Treatment Panel
III criteria, metabolic syndrome was defined by the
presence of 3 or more of the following criteria: 1) central
obesity defined as a waist circumference 102 cm in men
and 88 cm in women; 2) triglyceride level 150 mg/dl
(to convert to mmol/l, multiply by 0.0113); 3) high-
density lipoprotein (HDL) cholesterol level 40 mg/dl
(to convert to mmol/l, multiply by 0.0259) in men and
50 mg/dl in women; 4) blood pressure of 130/85 mm
Hg or higher; and 5) fasting glucose level of 110 mg/dl
(to convert to mmol/l, multiply by 0.0555) or higher.
Hypertension was diagnosed with Joint National Com-
mittee VI criteria (19).
Genotyping. Genotyping of rs5068 was carried out on 1,608
subjects with TaqMan (Applied Biosystems, Foster City,
California) according to the manufacturer’s instructions, with
10 to 20 ng DNA. Primers and probes were Assay-by Design
(Applied Biosystems). After polymerase chain reaction ampli-
fication, end reactions were read on the ABI Prism 7900ht
with Sequence Detection Software (Applied Biosystems). The
quality value percentage is a quality metric that indicates
the reliability of called genotypes generated by the SDS
software. The quality value was calculated with the ABI
proprietary calling algorithm determining how well that
sample fits into the cluster. Genotypes 95% are located
further from their clusters and have a lower reliability. An
electronic data file was generated that contains genotypes
and the quality value.
Natriuretic peptide assays. Plasma NT-proANP levels
were available in a subgroup of 1,485 subjects with a
radioimmunoassay (Phoenix Pharmaceuticals, Belmont,
California) (20). The NT-proBNP values were measured in
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cence immunoassay (Roche Diagnostics, Indianapolis, In-
diana) (21).
Doppler echocardiography. All echocardiograms were
performed with the same echocardiographic instrument
(HP-2500, Hewlett Packard, Palo Alto, California) and
were interpreted by a single echocardiologist blinded to
clinical data. Two-dimensional and color Doppler imag-
ing were performed to screen for valvular stenosis and
regurgitation. In each subject, ejection fraction was mea-
sured, and diastolic function was classified as mild,
moderate, and severe as previously described (17). Left
ventricular (LV) dimension and mass and left atrial
volume were calculated from M-mode and 2-dimensional
measurements, respectively, and were indexed to body
surface area (22–24). The LV mass was calculated ac-
cording to the Devereux formula. Presence of LV hyper-
trophy was defined based on LV mass index 130 g/m2
for men and 100 g/m2 for women (25). Presence of left
atrial enlargement was defined as left atrial volume index
33 ml/m2 in men and 30 ml/m2 in women (26).
tatistical analysis. Data pertaining to patient demo-
raphic information and clinical characteristics were sum-
arized with descriptive statistics. These included counts
nd percentages for categorical and ordinal variables or
edians and interquartile ranges for continuous variables.
o test for an association with the rs5068 genotype,
pecifically whether or not a subject had at least 1 copy of
he minor G allele, each clinical factor was modeled as the
ependent variable via linear regression (or logistic regres-
ion if the factor was binary) with rs5068 genotype as the
xplanatory variable. All modeling was performed unad-
usted and adjusted for potential confounding variables such
s age and sex. Further adjustments were done for BMI and
T-proANP. Due to highly skewed distributions of the
T-proANP and NT-proBNP biomarkers, a probit trans-
ormation was applied to the ranked values of each, thus
roducing normal distributional properties. Similarly, other
kewed variables, including C-reactive protein (CRP), se-
um glucose, insulin, and triglycerides levels, were trans-
ormed to approximate normality with the logarithmic
ransform. Furthermore, because age and sex are highly
orrelated with these biomarkers and with several other
linical factors, both were treated as adjusting covariates in
he logistic models to control for their potential confound-
ng. Although multiple hypothesis tests were carried out, a
ominal 2-sided significance level of 0.05 was used with no
ormal adjustment for multiple testing. Given that approx-
mately 30 to 40 variables were evaluated, the expected
umber of approximately 1 or 2 nominally significant results
y chance alone should be considered in the interpretation
f our findings. All analyses were carried out with the SAS
tatistical software package (version 8.2, SAS Institute, Inc.,
ary, North Carolina). wesults
revalence of rs5068 and circulating natriuretic peptides.
rom collected DNA samples on 2,027 subjects, a total of
,608 subjects were successfully genotyped and included in
his study. Genotype frequencies of rs5068 were AA: 89.9%
n  1,445), AG: 9.7% (n  157), and GG: 0.4% (n  6),
orresponding to a minor allele frequency of 5.3%. The
istribution was in Hardy-Weinberg equilibrium (p 
.435). Due to the low frequency of homozygotes for the G
llele, all analyses were performed assuming a dominant model
ith AG and GG genotypes combined. The characteristics of
he study population are summarized in Table 1. Neither age
or sex were significantly associated with the genotype, al-
hough there was a trend toward a higher prevalence of women
mong those who had at least 1 minor allele compared with
hose with none (58% vs. 52%, age-adjusted p  0.122).
mportantly, the presence of at least 1 copy of the minor allele
as associated with increased plasma levels of NT-proANP
median 2,584 vs. 2,188 pg/ml), both unadjusted (p 0.001),
nd after adjustment for age, sex, and BMI (p  0.006). In
ontrast, circulating levels of NT-proBNP were not signifi-
antly different between genotypes.
ardiovascular phenotype. The G allele was significantly
ssociated, controlling for age and sex, with lower systolic
lood pressure (SBP) (delta  4.28 mm Hg, p  0.011)
ut not with diastolic BP (delta  1.24 mm Hg, p 
.132) (Table 1). The effect on SBP remained marginally
ignificant after adjusting for BMI (p  0.051) or further
djusting for NT-proANP (p  0.054). The analysis of left
trial volume and LV structure and function as determined
y echocardiography (LV ejection fraction, LV dimensions,
V mass, and LV volume index) did not reveal any
ignificant associations with the rs5068 genotype.
With regard to cardiovascular diseases in a model ad-
usted for age and sex, the regression analysis showed that
ewer minor allele carriers of rs5068 had a history of
yocardial infarction (adjusted odds ratio: 0.29, p  0.042),
hereas in a model adjusted also for BMI, the result was
lightly attenuated (odds ratio: 0.32, p  0.061) (Table 2).
here was no significant association between genotype and
ypertension, coronary artery disease, congestive heart failure,
trial fibrillation, or cerebrovascular accident.
etabolic phenotype. In a regression model adjusted for
ge and sex, the presence of at least 1 copy of the G allele
as associated with lower BMI (delta  1.22 kg/m2, p 
0.006) (Table 3) and waist circumference (delta  2.45
cm, p 0.021) as well as reduced rate of obesity (odds ratio:
0.54, p 0.002) (Fig. 1A). In addition, the minor allele was
associated with higher levels of HDL cholesterol (delta 
2.46 mg/dl, p  0.019), lower plasma values of CRP (0.17
s. 0.20 mg/dl, p  0.027) (Table 3), and—although not
ignificant—with lower levels of insulin in subjects free of
iabetes mellitus type 1 and 2 (4.7 U/ml vs. 5.2 U/ml, p
 0.069) (Table 3). Moreover, having at least 1 minor alleleas associated with lower prevalence of metabolic syndrome
retic pe
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between the rs5068 minor allele HDL cholesterol and CRP
values and metabolic syndrome failed to remain significant
(Table 3), after including BMI in the regression model.
However, the association of the G allele with BMI, obesity,
and waist circumference remained significant after adjusting
for NT-proANP. Genotypes did not differ with regard to
plasma concentration of total and low-density lipoprotein
cholesterol, triglycerides, and fasting glucose (Table 3). Of
note, the proportion of subjects with anti-lipemic treatment
was similar between the 2 genotype groups (17% in both), as
was the prevalence of diabetes mellitus type 2 (Table 2).
Discussion
Although ANP and BNP have been known to play a
fundamental role in cardiorenal homeostasis, significant
metabolic actions of natriuretic peptides have only recently
Characteristics of the Study Population Across the rs5068 GenotyTable 1 Characteristics of the Study Population Across the rs5
Characteristic
AA
(n  1,445)
Women 746 (52%) 95
Age, yrs 61.5 (53.2, 70.4) 62.5
Age categories, yrs
45–54 436 (30%) 41
55–64 433 (30%) 53
65–74 367 (25%) 39
75 209 (14%) 30
Systolic blood pressure, mm Hg 132 (116, 147) 129
Diastolic blood pressure, mm Hg 73 (67, 80) 72
Creatinine, mg/dl 1.0 (0.9, 1.2) 1.0
NT-proBNP, pg/ml 67.4 (27.8, 146.9) 80.2
NT-proANP, pg/ml 2,188 (1,374, 3,238) 2,584
Ejection fraction, % 65 (60, 68) 65
Ejection fraction 40% 28 (2%) 1
Ejection fraction 50% 83 (6%) 6
Moderate-to-severe diastolic dysfunction 106 (7%) 11
LV dimension index, cm/m2 2.6 (2.4, 2.8) 2.6
LV mass index, g/m2 94 (82, 109) 93
LA volume index, ml/m2 23.3 (19.5, 28.4) 23.9
Values are counts (%) or median (25th and 75th percentile). *p value obtained from univariate regr
regression model adjusting for age, sex, and body mass index (BMI). §p value obtained from regres
reflect probit transformation applied to rank-ordered NT-proANP and N-terminal pro–B-type natriu
LA  left atrial; LV  left ventricular.
Prevalence of Cardiovascular Diseases and Diabetes Mellitus TypeTable 2 Prevalence of Cardiovascular Diseases and Diabetes M
Characteristic
AA
(n  1,445)
AG  GG
(n  163)
Odd
Verified hypertension 425 (29%) 47 (29%) 0.97 (
Coronary artery disease 185 (13%) 14 (9%) 0.64 (
Myocardial infarction 80 (6%) 3 (2%) 0.32 (
Congestive heart failure 31 (2%) 5 (3%) 1.44 (
Atrial fibrillation 68 (5%) 10 (6%) 1.32 (
Cerebrovascular accident 20 (1%) 4 (2%) 1.79 (
Diabetes mellitus type 2 108 (7%) 13 (8%) 1.07 (*Odds ratio, 95% confidence interval (CI), and p value obtained from logistic regression univariate model
sex. ‡Odds ratio, 95% CI, and p value obtained from logistic regression model adjusting for age, sex, andemerged. Here we report for the first time that an ANP
genetic variant associated with higher NT-proANP levels is
associated with a favorable metabolic profile, primarily via
its association with BMI, and that it is also associated with
a favorable cardiovascular profile. Specifically, according to a
regression analysis adjusted for age and sex, the minor allele
of the NPPA SNP rs5068 correlates not only with reduced
SBP and lower prevalence of myocardial infarction but also
with lower BMI, prevalence of obesity, waist circumference,
higher levels of HDL cholesterol, as well as lower values of
CRP. Carriers of the minor allele are also characterized by
a lower risk of metabolic syndrome.
In our study of residents in Olmsted County, Minnesota,
the genotype frequencies for rs5068 were similar to the
recently reported Framingham Heart Study and Malmö
Diet and Finrisk97 cohorts (6). We observed that the G
allele was associated with increased levels of NT-proANP,
Genotype
GG
63)
Unadjusted
p Value*
Adjusted
p Value†
Adjusted
p Value‡
Adjusted
p Value§
) 0.108 0.122 0.173 0.396
, 71.6) 0.182 0.208 0.300 0.998
0.183 0.211 0.295 0.935
)
)
)
)
, 144) 0.063 0.011 0.051 0.054
7) 0.063 0.132 0.247 0.262
1.1) 0.283 0.437 0.479 0.450
, 175.1) 0.096 0.413 0.497 0.565
3, 3,842)  0.001 0.002 0.006 —
5) 0.701 0.916 0.897 0.642
0.254 0.247 0.284 0.207
0.279 0.267 0.323 0.229
0.627 0.458 0.432 0.173
2.8) 0.236 0.321 0.910 0.689
07) 0.297 0.315 0.565 0.337
, 27.9) 0.377 0.211 0.314 0.085
odel. †p value obtained from regression model adjusting for age and sex. ‡p value obtained from
del adjusting for age, sex, BMI, and N-terminal pro-atrial natriuretic peptide (NT-proANP). p values
ptide (NT-proBNP) values.
ross the rs5068 Genotypes Type 2 Across the rs5068 Genotype
o (95% CI)
lue]*
Odds Ratio (95% CI)
[p Value]†
Odds Ratio (95% CI)
[p Value]‡
.39) [0.879] 0.91 (0.63–1.31) [0.600] 1.01 (0.69–1.48) [0.950]
.13) [0.124] 0.57 (0.31–1.05) [0.071] 0.61 (0.33–1.12) [0.109]
.02) [0.055] 0.29 (0.09–0.96) [0.042] 0.32 (0.10–1.06) [0.061]
.77) [0.453] 1.40 (0.52–3.74) [0.504] 1.57 (0.58–4.23) [0.373]
.63) [0.421] 1.29 (0.63–2.64) [0.487] 1.35 (0.66–2.77) [0.417]
.31) [0.292] 1.76 (0.59–5.26) [0.311] 1.79 (0.60–5.37) [0.300]
.95) [0.818] 1.05 (0.57–1.93) [0.875] 1.26 (0.68–2.35) [0.459]pe068
AG 
(n  1
(58%
(54.6
(25%
(33%
(24%
(18%
(115
(66, 7
(0.9,
(37.8
(1,69
(60, 6
(1%)
(4%)
(7%)
(2.4,
(82, 1
(19.2
ession m
sion mo2 Acellitu
s Rati
[p Va
0.68–1
0.36–1
0.10–1
0.55–3
0.67–2
0.61–5
0.59–1. †Odds ratio, 95% CI, and p value obtained from logistic regression model adjusting for age and
body mass index.
p of su
.
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is notable, because Itoh et al. (27) reported that it is
produced in equimolar amounts with ANP and represents a
robust estimator of ANP secretion from the heart (28).
Although a major stimulus for ANP release is increased
atrial stretch, there is no indication that this would explain
the higher levels associated with the minor allele in our
study, because there were no differences in terms of conges-
tive heart failure, atrial fibrillation or left atrial enlargement
across genotypes. Moreover, BP levels were lower in the
group characterized by the presence of the minor allele.
Newton-Cheh et al. (6) speculated that rs5068, which is
located in the 3’ untranslated region, could affect transcript
stability and result in higher ANP production. These
investigators pointed out that this mechanism would not
explain the higher BNP levels seen in their study, the levels
of which would be expected to decrease in a compensatory
manner if the primary mechanism was an increase in ANP
production. They propose an alternative explanation that
rs5068 resides in a shared enhancer element that coordi-
nately regulates expression of the adjacent NPPA and NPPB
genes. However, unlike in the study by Newton-Cheh et al.
(6), levels of NT-proBNP were not different between
genotypes in our cohort. This discrepancy could be a
consequence of the smaller size of the sample analyzed in
our study as well as the different assay performed.
Given the known metabolic effects of natriuretic peptides
and the increased levels of NT-proANP and NT-proBNP
associated with the rs5068 minor allele, it was our main
objective to define the metabolic phenotype associated with
the rs5068 genotype. Indeed, minor allele carriers not only
showed a favorable cardiovascular profile characterized by
lower SBP and lower prevalence of myocardial infarction,
but they also had a favorable metabolic phenotype charac-
terized by lower BMI, waist circumference, and prevalence
of obesity. Furthermore, they had higher levels of HDL
cholesterol and lower levels of CRP. The differences in
Metabolic Parameters in the Study Population According to the rs5Table 3 Metabolic Parameters in the Study Population Accordi
Characteristic
AA
(n  1,445)
AG  GG
(n  163)
BMI, kg/m2 27.9 (25, 31.6) 26.7 (24.3, 29.4
Obesity (BMI 30 kg/m2) 503 (35%) 36 (22%)
Waist circumference, cm 93 (82, 101) 90 (80, 96)
Total cholesterol, mg/dl 200 (178, 222) 207 (183, 231)
HDL cholesterol, mg/dl 42 (35, 54) 47 (39, 58)
LDL cholesterol, mg/dl 125 (105, 146) 133 (108, 154)
Triglycerides, mg/dl¶ 129 (95, 182) 123 (88, 169)
Serum glucose, mg/dl¶ 94 (89, 101) 93.0 (89, 101)
Insulin, U/ml¶# 5.2 (3.6, 7.8) 4.7 (3.5, 7.2)
C-reactive protein, mg/dl¶ 0.20 (0.09, 0.44) 0.17 (0.07, 0.40
Metabolic syndrome 296 (20%) 21 (13%)
Values are counts (%) or median (25th and 75th percentile). *p value obtained from univariate regr
regression model adjusting for age, sex and BMI. §p value obtained from regression model adjusti
and NT-proANP only. ¶p values based on logarithmic transformed variable. #Analyzed on subgrou
HDL  high-density lipoprotein; LDL  low density lipoprotein; other abbreviations as in Table 1HDL and CRP cannot be explained by anti-lipemic treat-ment, because both genotypes were similar in this regard.
Consistent with all these findings, the prevalence of the
metabolic syndrome in our study population was lower in
the minor allele carriers.
These associations support, once more, the view of a
significant, clinically relevant metabolic action of natriuretic
peptides, more specifically ANP. Interestingly, Miyashita et
al. (14) provided recent important findings with regard to
the critical role of natriuretic peptides and guanylyl
cyclase-A receptor stimulation in lipid catabolism and
glucose intolerance. Transgenic mice overexpressing BNP
were protected against obesity and insulin resistance in-
duced by high-fat diet, whereas transgenic mice overex-
pressing cGMP-dependent protein kinase revealed a signif-
icant reduction in body weight and higher insulin sensitivity
compared with wild-type mice, even on standard diet. Both
models showed augmented muscle mitochondrial biogenesis
and fat oxidation. Of note, acute infusion of ANP in
humans has been reported to promote insulin secretion and
inhibit glucagon secretion (29,30). However, in our study
this direct insulin-increasing effect of ANP is likely to be
offset by the favorable metabolic status of rs5068 minor
allele carriers, who would be expected to have improved
insulin sensitivity and thus generally lower insulin levels.
Although our study is an association study that cannot
establish a causal relationship between increased NT-proANP
and cardiovascular-metabolic phenotype, our findings support
the emerging metabolic role of guanylyl cyclase-A activation.
The capacity of ANP and BNP to promote lipid mobilization
and oxidation, slow gastric emptying, decrease blood pressure
and body weight, and increase insulin sensitivity provides
strong arguments in favor of the capacity of the natriuretic
peptide/guanylyl cyclase-A/cGMP signaling system to en-
hance metabolic function and phenotype (6,8,13,14).
Moreover, our findings support the hypothesis that the
presence of at least 1 copy of the minor allele of rs5068
Genotypethe rs5068 Genotype
Unadjusted
p Value*
Adjusted
p Value†
Adjusted
p Value‡
Adjusted
p Value§
0.003 0.006 — 0.006
0.001 0.002 — 0.001
0.006 0.021 — 0.025
0.190 0.274 0.301 0.336
0.004 0.019 0.115 0.205
0.296 0.275 0.280 0.197
0.102 0.096 0.295 0.234
0.573 0.535 0.960 0.486
0.059 0.069 0.446 0.469
0.083 0.027 0.220 0.120
0.024 0.025 0.286 0.133
odel. †p value obtained from regression model adjusting for age and sex. ‡p value obtained from
ge, sex, BMI, and NT-proANP. BMI not adjusted for in the model; adjusting factors were age, sex,
bjects free of diabetes mellitus type 1 and 2.068ng to
)
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ng for aassociated with higher circulating level of NT-proANP
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and metabolic diseases.
Despite no formal adjustment for multiple comparisons,
the consistency of the main significant findings with previ-
ous results as well as the number of significant findings tend
to support the association between the minor allele of
rs5068 and a favorable cardiometabolic phenotype. We
acknowledge that a potential criticism of the study is that
significant associations with multiple comparisons occurred
by chance. On the basis of the null distribution of p values
from the approximately 40 unique associations tested, the
expected number of type I errors for this study is 2 (i.e., on
average, 2 associations detected as nominally significant at
the 0.05 level would have occurred by chance alone).
Because there were a total of 6 such associations detected
(counting the significant results for BMI, obesity, and waist
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Figure 1 Prevalence of Obesity and Metabolic Syndrome
in the Study Population According to Genotype
(A) Prevalence of obesity in the study population according to genotype. Obe-
sity was defined as body mass index 30 kg/m2. (B) Prevalence of metabolic
syndrome in the study population according to genotype. p value obtained
from logistic regression model adjusting for age and sex.circumference as only 1)—more than the expected chancefinding—and because several of these associations with the
rs5068 genotype reflected a consistent protective effect on
cardiometabolic parameters, it is unlikely that chance alone
explains the associations. The results might not meet a strict
threshold for multiple testing, but given the a priori hypoth-
esis and experimental data, the findings seem plausible.
We also note that the associations between the G allele
and values of HDL cholesterol, CRP, metabolic syndrome,
and myocardial infarction were attenuated after fitting a
regression model adjusted for age, sex, and BMI. These data
could reveal how these metabolic associations might be
mediated by the primary important correlation between the
NPPA SNP and lower BMI. We further performed a
regression analysis including NT-proANP in our model.
The associations between the minor allele of rs5068 and
BMI, prevalence of obesity, and values of waist circumfer-
ence still remained significant, whereas the associations
between genotype and SBP and myocardial infarction re-
mained marginally significant. These findings should be
interpreted cautiously. Indeed, our data might indicate that
rs5068 or genetic loci in linkage disequilibrium with it
might affect susceptibility for cardiometabolic diseases.
There is also the possibility that rs5068 alters lifelong levels
of ANP, and this effect is not completely accounted for by
the measurement of 1 value of NT-proANP in each
individual. Moreover, it is important to remark that a lack of
attenuation after assuming a regression model adjusted for
NT-proANP does not exclude a possible biological role for
ANP in determining the observed favorable metabolic
phenotype. With respect to detection of a relationship between
plasma ANP levels and metabolic phenotype, we were proba-
bly limited by the size of our sample, our ability to directly
measure ANP due to the short half-life of ANP, and instability
of the peptide under laboratory conditions. Although we tested
for an association, we did not detect any difference between
groups with respect to plasma ANP levels.
Our model considered, as a confounding variable, not ANP
but NT-proANP, which was significantly higher in the group
characterized by the presence of the minor allele. Indeed,
NT-proANP is secreted in equimolar amounts with ANP
(27). Due to its longer half-life, greater laboratory stability, and
less variability in plasma concentration, NT-proANP is con-
sidered a reliable biomarker to estimate ANP secretion from
the heart (27,28), but there is no evidence in published reports
regarding a biological action of NT-proANP. On the contrary,
several findings support the view of ANP as an important
metabolic regulator. Infusion of ANP at pharmacological doses
into healthy lean men and head-down bed rest position, both
of which increase plasma ANP levels, promote lipid mobiliza-
tion and use (8,31). This lipolytic effect of ANP is independent
of insulin or sympathetic nervous system activation and is
mediated by a cGMP-dependent pathway that induces the
phosphorylation of hormone-sensitive lipase and perilipin A
via the activation of cGMP-dependent protein kinase I
(32,33). Furthermore, in a key Framingham study, NT-
proANP and BNP correlated inversely with the metabolic
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for BMI (34).
A replication study is clearly needed to confirm the
validity of our data, and the lack of replication in the current
study is a limitation. An additional limitation is the low
genotyping call rate. To support the validity of our findings
from a statistical point of view, we can assume that the
failures occurred in a random fashion unrelated to any
phenotype traits. Indeed, the genotype frequencies of
rs5068 in our population are similar to the frequencies
reported in the HapMap Project with regard to a population
from Utah, in the Framingham Heart Study, Malmö Diet
and Finrisk cohort.
Our investigation together with previous experimental
data provide a rationale for the development of ANP or
guanylyl cyclase-A agonist/ANP/BNP-like drugs as poten-
tial cardiometabolic therapeutics that are able to target the
complex metabolic syndrome on several different levels.
Indeed, our recent report of the feasibility of orally delivered
BNP in an animal model of experimental hypertension
supports such a therapeutic direction (35,36). Further stud-
ies are required to confirm our findings and to clarify the
physiological mechanisms underlying the effects exerted by
natriuretic peptides on metabolism.
Conclusions
Our findings in a general community population demon-
strate that the minor allele of rs5068 is associated with a
favorable cardiometabolic profile characterized by higher
levels of NT-proANP and HDL cholesterol, lower SBP,
prevalence of myocardial infarction, BMI, waist circumfer-
ence, CRP levels, and prevalence of metabolic syndrome.
Our results, which both confirm previous findings regarding
a link to blood pressure and extend the relationship of
rs5068 to cardiometabolic homeostasis, suggest that rs5068
or genetic loci in linkage disequilibrium might affect sus-
ceptibility for cardiometabolic diseases. Replication studies
are needed to confirm our results. These findings support
the possible protective role of natriuretic peptides by their
favorable effects on metabolic function, including body
weight and lipid metabolism with clinical implications in
disease prevention and innovative therapeutics.
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